Hyperhomocysteinaemia as a cardiovascular risk factor: An update

Netherlands Journal of Medicine

Volumn 56, Issue 3, 2000, Pages 119-130

  Van der Griend, René ^a,c   Biesma, Douwe H ^a   Banga, Jan Dirk ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Folate; Homocysteine; Methionine loading test; Methylenetetrahydrofolate reductase; Pyridoxine

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; METHIONINE; PYRIDOXINE;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; LOADING TEST; POINT MUTATION; REVIEW; THROMBOSIS; VITAMIN DEFICIENCY;

ADULT; CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS;

EID: 0034160095     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(99)00132-1     Document Type: Review

References (127)

1. Mudd S.H., Levy H.L., Skovby F. Disorders of transsulfuration. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular bases of inherited disease. 7th ed :1995;1279-1327 McGraw-Hill, New York.
2. Mudd S.H., Skovby F., Levy H.L., et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 37:1985;1-31.
3. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 56:1969;111-128.
4. Wilcken D.E.L., Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest. 57:1976;1079-1082.
5. Stampfer M.J., Malinow M.R., Willett W.C., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc. 268:1992;877-881.
6. Perry I.J., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395-1398.
7. Arnesen E., Refsum H., Bønaa K.H., Ueland P.M., Førde D.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 24:1995;704-709.
8. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. New Engl J Med. 337:1997;230-236.
9. Wald N.J., Watt H.C., Law M.R., Weir D.G., McPartlin J., Scott J.M. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 158:1998;862-867.
10. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc. 274:1995;1049-1057.
11. Hopkins P.N., Wu L.L., Hunt S.C., James B.C., Vincent G.M., Williams R.R. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 15:1995;1314-1320.
12. Dalery K., Lussier-Cacan S., Selhub J., Davignon J., Latour Y., Genest J. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol. 75:1995;1107-1111.
13. Robinson K., Mayer E.L., Miller D.P., et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 92:1995;2825-2830.
14. Malinow M.R., Ducimetiere P., Luc G., et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis. 126:1996;27-34.
15. Verhoef P., Stampfer M.J., Buring J.E., et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamin B6, B12, and folate. Am J Epidemiol. 143:1996;845-859.
16. Graham I.M., Daly L.E., Refsum H.M., et al. Plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc. 277:1997;1775-1781.
17. Ridker P.M., Hennekens C.H., Selhub J., Miletich J.P., Malinow M.R., Stampfer M.J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 95:1997;1777-1782.
18. den Heijer M., Rosendaal F.R., Blom H.J., Gerrits W.B.J., Bos G.M.J. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 80:1998;874-877.
19. Hankey G.J., Eikelboom J.W. Homocysteine and vascular disease. Lancet. 354:1999;407-413.
20. Selhub J., Miller J.W. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 55:1992;131-138.
21. Boers G.H.J., Smals A.G.H., Trijbels F.J.M., et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. New Engl J Med. 313:1985;709-715.
22. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. New Engl J Med. 324:1991;1149-1155.
23. Kraus J.P., Le K., Swaroop M., et al. Human cystathionine β-synthase cDNA: sequence, alternative splicing and expression in cultured cells. Hum Mol Genet. 2:1993;1633-1638.
24. Gallagher P.M., Meleady R., Shields D.C., et al. Homocysteine and risk of premature coronary heart disease. Evidence from a common gene mutation. Circulation. 94:1996;2154-2158.
25. Kluijtmans L.A.J., van den Heuvel L.P.W.J., Boers G.H.J., et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 58:1996;35-41.
26. Kozich V., Kraus E., de Franchis R., et al. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine β-synthase alleles at the molecular level. Hum Mol Genet. 4:1995;623-629.
27. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10:1995;111-113.
28. Kang S.S., Passen E.L., Ruggie N., Wong P.W.K., Sora H. Thermolabile defect of methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 48:1991;536-545.
29. Engbersen A.M.T., Franken D.G., Boers G.H.J., Stevens E.M.B., Trijbels F.J.M., Blom H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 56:1995;142-150.
30. Jacques P.F., Bostom A.G., Williams R.R., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
31. Christensen B., Frosst P., Lussier-Cacan S., et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 17:1997;569-573.
32. Ma J., Stampfer M.J., Hennekens C.H., et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
33. Gallagher P.M., Meleady R., Shields D.C., et al. Homocysteine and risk of premature coronary heart disease. Evidence from a common gene mutation. Circulation. 94:1996;2154-2158.
34. Schmitz C., Lindpaintner K., Verhoef P., Gaziano J.M., Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. Circulation. 94:1996;1812-1814.
35. van Bockxmeer F.M., Mamotte C.D.S., Vasikaran S.D., Taylor R.R. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 95:1997;21-23.
36. Kluijtmans L.A.J., Kastelein J.J.P., Lindemans J., et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 96:1997;2573-2577.
37. Reinhardt D., Sigusch H.H., Vogt S.F., Farker K., Muller S., Hoffmann A. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur J Clin Invest. 28:1998;20-23.
38. Brattström L., Wilcken D.E.L., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The results of a meta-analysis. Circulation. 98:1998;2520-2526.
39. Kang S.S., Wong P.W.K., Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 36:1987;458-462.
40. Allen R.H., Stabler S.P., Savage D.G., Lindenbaum J. Diagnosis of cobalamin deficiency I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol. 34:1990;90-98.
41. Selhub J., Jacques P.F., Wilson P.W.F., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc. 270:1993;2693-2698.
42. Nygard O., Vollset S.E., Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. J Am Med Assoc. 274:1995;1526-1533.
43. Nygard O., Refsum H., Ueland P.M., et al. Coffee consumption and plasma total homocysteine: The Hordaland homocysteine study. Am J Clin Nutr. 65:1997;136-143.
44. Arnadottir M., Hultberg B., Nilsson-Ehle P., Thysell H. The effect of reduced glomerular rate on plasma total homocysteine concentration. Scand J Clin Lab Invest. 56:1996;41-46.
45. Stabler S.P., Marcell P.D., Podell E.R., Allen R.H. Quantitation of total homocysteine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry. Anal Biochem. 162:1987;185-196.
46. Bostom A.G., Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 52:1997;10-20.
47. Wouters M.G.A.J., Moorrees M.T.E.C., van der Mooren M.J., et al. Plasma homocysteine and menopausal status. Eur J Clin Invest. 25:1995;801-805.
48. Refsum H., Ueland P.M., Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res. 46:1986;5385-5391.
49. Ono H., Sakamoto A., Eguchi T., et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism. 46:1997;959-962.
50. Schwaninger M., Ringleb P., Winter R., et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia. 40:1999;345-350.
51. de Lorgeril M., Salen P., Paillard F., Lacan P., Richard G. Lipid-lowering drugs and homocysteine. Lancet. 353:1999;209-210.
52. Garg R., Malinow R., Pettinger M., Hunninghake D. Treatment with niacin increases plasma homocyst(e)ine levels. Circulation. 94:1996;I457. (Abstract).
53. Ueland P.M., Refsum H., Stabler S.P., Malinow R., Andersson A., Allen R.H. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 39:1993;1764-1779.
54. Andersson A., Isaksson A., Hultberg B. Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem. 38:1992;1311-1315.
55. Israelsson B., Brattström L., Refsum H. Homocysteine in frozen plasma samples: a short cut to establish hyperhomocysteinaemia as a risk factor for arteriosclerosis? Scand J Clin Lab Invest. 53:1993;465-469.
56. Alfthan G., Pekkanen J., Jauhiainen M., et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9-19.
57. Ubbink J.B., Vermaak W.J.H., van der Merwe A., Becker P.J. The effect of blood sample aging and food consumption on plasma total homocysteine levels. Clin Chim Acta. 207:1992;119-128.
58. Guttormsen A.B., Schneede J., Fiskerstrand T., Ueland P.M., Refsum H.M. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr. 124:1994;1934-1941.
59. Garg U.C., Zheng Z.-J., Folsom A.R., et al. Short-term and long-term variability of plasma homocysteine measurement. Clin Chem. 43:1997;141-145.
60. van den Berg M., de Jong S.C., Devillé W., et al. Variability of fasting and post-methionine plasma homocysteine levels in normo- and hyperhomocysteinaemic individuals. Neth J Med. 55:1999;29-38.
61. Lindgren A., Brattström L., Norrving B., Hultberg B., Andersson A., Johansson B.B. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 26:1995;795-800.
62. Landgren F., Israelsson B., Lindgren A., Hultberg B., Andersson A., Brattström L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med. 237:1995;381-388.
63. Egerton W., Silberberg J., Crooks R., Ray C., Xie L., Dudman N. Serial measurements of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol. 77:1996;759-761.
64. Sardharwalla I.B., Fowler B., Robins A.J., Komrower G.M. Detection of heterozygotes for homocystinuria. Study of sulphur-containing amino acids in plasma and urine after L-methionine loading. Arch Dis Child. 49:1974;553-559.
65. Bostom A.G., Jacques P.F., Nadeau M.R., Williams R.R., Ellison R.C., Selhub J. Post-methionine load hyperhomocysteinenemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis. 116:1995;147-151.
66. van der Griend R., Haas F.J.L.M., Duran M., Biesma D.H., Meuwissen O.J.A.Th., Banga J.D. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med. 132:1998;67-72.
67. van den Berg M., Stehouwer C.D.A., Bierdrager E., Rauwerda J.A. Plasma homocysteine and severity of atherosclerosis in young patients with lower extremity atherosclerotic disease. Arterioscler Thromb Vasc Biol. 16:1996;165-171.
68. Ueland P.M., Refsum H., Brattström L. Plasma homocysteine and cardiovascular disease. Francis R.B. Jr. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. 1992;183-236 Marcel Dekker, New York.
69. Verhoef P., Kok F.J., Kruyssen D.A.C.M., et al. Plasma total homocysteine, B-vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 17:1997;989-995.
70. den Heijer M., Bos G.M.J., Brouwer I.A., Gerrits W.B.J., Blom H.J. Variability of the methionine loading test: no effect of a low protein diet. Ann Clin Biochem. 33:1996;551-554.
71. Brattström L.E., Israelsson B., Norrving B., et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis. 81:1990;51-60.
72. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood. 90:1997;1-11.
73. Verhoef P., Kok F.J., Kluijtmans L.A.J., et al. The 677C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary artery disease. Atherosclerosis. 132:1997;105-113.
74. de Jong S.C., Stehouwer C.D.A., van den Berg M., et al. Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease. Arterioscler Thromb Vasc Biol. 19:1999;1316-1324.
75. den Heijer M, Bos GMJ, van der Boor RPGM et al., Mutated methylenetetrahydrofolate reductase and other determinants of plasma homocysteine before and after methionine loading in a general Dutch population. In: den Heijer M, editor. Hyperhomocysteinemia and venous thrombosis [dissertation]. Leiden Univ., 1997:37-55.
76. Boers G.H.J. Hyperhomocysteinaemia: a newly recognized risk factor for vascular disease. Neth J Med. 45:1994;34-41.
77. Selhub J., Jacques P.F., Bostom A.G., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. New Engl J Med. 332:1995;286-291.
78. Alfthan G., Aro A., Gey K.F. Plasma homocysteine and cardiovascular disease mortality. Lancet. 349:1997;397.
79. Hoogeveen E.K., Kostense P.J., Beks P.J., et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus. A population-based study. Arterioscler Thromb Vasc Biol. 18:1998;133-138.
80. Malinow M.R., Nieto F.J., Szklo M., Chambless L.E., Bond G. Carotid artery intima-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The atherosclerosis risk in communities study. Circulation. 87:1993;1107-1113.
81. Verhoef P., Hennekens C.H., Malinow M.R., Kok F.J., Willett W.C., Stampfer M.J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 25:1994;1923-1930.
82. Chasan-Taber L., Selhub J., Rosenberg I.H., et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 15:1996;136-143.
83. Verhoef P., Hennekens C.H., Allen R.H., Stabler S.P., Willett W.C., Stampfer M.J. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol. 79:1997;799-801.
84. Evans R.W., Shaten B.J., Hempel J.D., Cutler J.A., Kuller L.H. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol. 17:1997;1947-1953. For the MRFIT Research Group.
85. Folsom A.R., Nieto F.J., McGovern P.G., et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 98:1998;204-210.
86. Stehouwer C.D.A., Weijenberg M.P., van den Berg M., Jakobs C., Feskens E.J.M., Koromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men. A 10-year follow-up. Arterioscler Thromb Vasc Biol. 18:1998;1895-1901.
87. Rimm E.B., Willet W.C., Hu F.B., et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. J Am Med Assoc. 279:1998;359-364.
88. Verhaar M.C., Wever R.M.F., Kastelein J.J.P., van Dam T., Koomans H.A., Rabelink T.J. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 97:1998;237-241.
89. Robinson K., Arheart K., Refsum H., et al. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation. 97:1998;437-443. For the European COMAC Group.
90. Harker L.A., Slichter S.J., Scott C.R., Ross R. Homocystinemia: vascular injury and arterial thrombosis. New Engl J Med. 291:1974;537-543.
91. Harker L.A., Ross R., Slichter S.J., Scott C.R. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 58:1976;731-741.
92. Starkebaum G., Harlan J.M. Endothelial cell injury due to copper-catalyzed hydrogen peroxidase generation from homocysteine. J Clin Invest. 77:1986;1370-1376.
93. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 98:1996;5-7.
94. Heinecke J.W., Kawamura M., Suzuki L., Chait A. Oxidation of low-density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res. 34:1993;2051-2061.
95. Tsai J.-C., Perrella M.A., Yoshizumi M., et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 91:1994;6369-6373.
96. Majors A., Ehrhart L.A., Pezacka E.H. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 17:1997;2074-2081.
97. Lentz S.R., Sobey C.G., Piegors D.J., et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 98:1996;24-29.
98. Rodgers G.M., Kane W.H. Activation of endogenous factor V by a homocysteine-induced vascular endothelial activator. J Clin Invest. 77:1986;1909-1916.
99. Rodgers G.M., Conn M.T. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 75:1990;895-901.
100. Lentz S.R., Sadler J.E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 88:1991;1906-1914.
101. Nishinaga M., Ozawa T., Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 92:1993;1381-1386.
102. Fryer R.H., Wilson B.D., Gubler D.B., Fitzgerald L.A., Rodgers G.M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 13:1993;1327-1333.
103. Hajjar K.A. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 91:1993;2873-2879.
104. Stamler J.S., Osborne J.A., Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 91:1993;308-318.
105. Upchurch G.R. Jr., Welch G.N., Fabian A.J., et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 272:1997;17012-17017.
106. Tawakol A., Omland T., Gerhard M., Wu J.T., Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 95:1997;1119-1121.
107. Woo K.S., Chook P., Lolin Y.I., et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 96:1997;2542-2544.
108. Chambers J.C., McGregor A., Jean-Marie J., Obeid O.A., Kooner J.S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation. 99:1999;1156-1160.
109. Bellamy M.F., McDowell I.F.W., Ramsey M.W., Brownlee M., Newcombe R.G., Lewis M.J. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest. 29:1999;659-662.
110. Nappo F., de Rosa N., Marfella R., et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. J Am Med Assoc. 281:1999;2113-2118.
111. De Valk-de Roo G.W., Stehouwer C.D.A., Lambert J., et al. Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women. Clin Chem. 45:1999;1200-1205.
112. Lambert J., van den Berg M., Steyn M., Rauwerda J.A., Donker A.J.M., Stehouwer C.D.A. Familial hyperhomocysteinaemia and endothelium-dependent vasodilation and arterial distensibility of large arteries. Cardiovasc Res. 42:1999;743-751.
113. Barber G.W., Spaeth G.L. Pyridoxine therapy in homocystinuria. Lancet. i:1967;337.
114. Dickinson C.J. Does folic acid harm people with vitamin B12 deficiency? Q J Med. 88:1995;357-364.
115. Campbell N.R.C. How safe are folic acid supplements? Arch Intern Med. 156:1996;1638-1644.
116. Schaumburg H., Kaplan J., Windebank A., et al. Sensory neuropathy from pyridoxine abuse. New Engl J Med. 309:1983;445-448.
117. Parry G.J., Bredesen D.E. Sensory neuropathy with low-dose pyridoxine. Neurology. 35:1985;1466-1468.
118. Savage D.G., Lindenbaum J. Folate-cobalamin interactions. Bailey L.B. Folate in health and disease. 1995;237-285 Marcel Dekker, New York, NY.
119. de Jong S.C., Stehouwer C.D.A., van den Berg M., Geurts T.W., Bouter L.M., Rauwerda J.A. Normohomocysteinemia and vitamin-treated hyperhomocysteinemia are associated with similar risk of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. J Intern Med. 246:1999;87-96.
120. Taylor L.M., Defrang R.D., Harris E.J. Jr., Porter J.M. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 13:1991;128-136.
121. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br Med J. 316:1998;894-898.
122. Ubbink J.B., Vermaak W.J.H., van der Merwe A., Becker P.J., Delport R., Potgieter H.C. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 124:1994;1927-1933.
123. Franken D.G., Boers G.H.J., Blom H.J., Trijbels J.M.F. Effect of various regimens of vitamin B6 and folic acid on mild hyperhomocysteinaemia in vascular patients. J Inherit Metab Dis. 17:1994;159-162.
124. van den Berg M., Franken D.G., Boers G.H.J., et al. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg. 20:1994;933-940.
125. Leeda M., Riyazi N., de Vries J.I.P., Jakobs C., van Geijn H.P., Dekker G.A. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol. 179:1998;135-139.
126. Ubbink J.B., van der Merwe A., Delport R., et al. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest. 98:1996;177-184.
127. Bostom A.G., Gohh R.Y., Bealieu A.J., et al. Treatment of hyperhomocysteinemia in renal transplant recipients. Ann Intern Med. 127:1997;1089-1092.